HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- AI an emerging tool, not substitute, for oncologists
-
- Will advances in AI lead to more effective screening practices for ovarian cancer?
- America’s new cancer: History repeats itself Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Immunotherapy effective for many patients ineligible for registration trials, but caution necessary Jai N. Patel, PharmD, BCOP, CPP
- Nephrotoxicity among young patients with cancer: Not only an acute problem Lisa Triche, DNP, RN, CPNP
- Researchers investigate power of human-animal interactions among children with cancer
- Enrollment on genomically matched clinical trials improves sarcoma outcomes
- BLU-667 active, safe in RET fusion-positive non-small cell lung cancer
- Men choosing active prostate cancer surveillance show low rates of follow-up monitoring
-
- Alternative pembrolizumab, nivolumab dosing methods decrease cost
- Enzalutamide improves OS for metastatic hormone-sensitive prostate cancer
- Trastuzumab emtansine provides effective, less toxic neoadjuvant therapy for HER2-positive breast cancer
- Perioperative chemotherapy feasible for resectable pancreatic adenocarcinoma
- Nab-paclitaxel plus gemcitabine may benefit some patients with surgically resected pancreatic cancer
- Majority of gynecologic oncologists, female and male, experience sexual harassment, survey shows
- Treatment with ibrutinib, acalabrutinib for chronic lymphocytic leukemia may increase risk for second cancers
- Investigational CAR T-cell therapy induces durable responses in pretreated leukemia subtypes
-
- $94 billion in earnings, 8.7 million years of life lost to cancer in 2015
- Targeted drug delivery reduces costs for management of cancer-related pain
- Voxelotor increases hemoglobin levels, reduces hemolysis markers in sickle cell disease
- European guidelines recommend letermovir as CMV prophylaxis in HSCT recipients
- FDA approves Keytruda for first-line treatment of head and neck squamous cell carcinoma
- FDA approves Bavencio-Inlyta combination for advanced renal cell carcinoma
- FDA approves Venclexta-Gazyva regimen for untreated chronic lymphocytic leukemia
- FDA grants fast track designation to momelotinib for myelofibrosis
-
- The University of Texas MD Anderson Cancer Center ranked best cancer hospital in nation
- Foundation to present leadership award to Memorial Sloan Kettering lymphoma specialist
- University of Arizona Cancer Center appoints associate director for basic sciences
- American Lung Association honors UCLA cancer researcher